Form 4: Collegium Pharmaceutical EVP Colleen Tupper Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Colleen Tupper, EVP & Chief Financial Officer of Collegium Pharmaceutical, sold shares of common stock on March 20 and 21, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Colleen Tupper, the EVP & Chief Financial Officer of Collegium Pharmaceutical, sold shares of the company's common stock on March 20 and March 21, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on August 14, 2024.
- On March 20, 2025, 1,206 shares were sold at a weighted average price of $30.0011, with prices ranging from $30.00 to $30.01.
- On March 21, 2025, 6,396 shares were sold at a weighted average price of $30.0295, with prices ranging from $30.00 to $30.50.
- Following these transactions, Ms. Tupper directly owns 156,667 shares of Collegium Pharmaceutical common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The document simply reports stock sales under a pre-arranged plan, which doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Executive stock sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-planned. However, investors often monitor these sales for insights into management's perspective on the company's valuation and future prospects.
Comparison to Industry Standards
- Executive compensation and stock ownership are typical components of corporate governance.
- Rule 10b5-1 trading plans are a standard method used by corporate insiders to sell shares while avoiding accusations of insider trading.
- Comparing Colleen Tupper's stock ownership to that of other CFOs in similar-sized pharmaceutical companies could provide context, but that data isn't available in this document.
Stakeholder Impact
- Shareholders may be interested in executive stock sales as an indicator of management's confidence in the company.
- However, sales under a 10b5-1 plan are generally less concerning as they are pre-planned.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date the Rule 10b5-1 trading plan was adopted by Colleen Tupper. |
| 03/20/2025 | Date of the first reported transaction: sale of 1,206 shares. |
| 03/21/2025 | Date of the second reported transaction: sale of 6,396 shares. |
| 03/24/2025 | Date of the signature on the Form 4 filing. |
Keywords
Form 4, Collegium Pharmaceutical, Colleen Tupper, Executive Stock Sale, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.